‹ All stocks
NeuroSense Therapeutics Ltd.
NRSNW · NASDAQ · Healthcare
$0.04
▼ $0.01 (-12.00%)
Day range
$0.04 – $0.06
Year range
$0.04 – $0.54
Open
$0.06
Previous close
$0.05
Market cap
$976.80K
Volume (24h)
$7.8K
Volume (52w)
$311
Performance
7D
▼ -12.00%
1M
▼ -13.91%
3M
▼ -34.00%
6M
▼ -80.00%
1Y
▼ -89.58%
YTD
▼ -86.85%
3Y
▼ -64.00%
5Y
▼ -96.08%
All-time
▼ -96.08%
Key statistics
P/E ratio
-0.01
EPS (TTM)
$-6.24
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
24.7M
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.
Visit websiteCountry: United States of America
More in Healthcare
LLY Eli Lilly and Company |
$1143.12 | -0.59% |
JNJ Johnson & Johnson |
$252.93 | -2.22% |
ABBV AbbVie |
$265.76 | 2.20% |
MRK Merck & Co. |
$139.54 | -2.97% |
UNH UnitedHealth Group Incorp… |
$378.58 | 3.66% |